Who are ABROCITINIB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqselvi, Cibinqo, Cibinqo, Jyseleca, JAK Inhibitor, Abrocitinib Suspension F6.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl3655081.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ABROCITINIB — Competitive Intelligence Brief

ABROCITINIB (ABROCITINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Janus Kinase Inhibitor [EPC].

marketed Janus Kinase Inhibitor [EPC] JAK1 Small molecule Live · refreshed every 30 min

Target snapshot

ABROCITINIB (ABROCITINIB). CIBINQO works by reversibly inhibiting JAK1, blocking ATP binding and showing selectivity over other JAKs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABROCITINIB TARGET	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Jyseleca	FILGOTINIB	Gilead Sciences Ireland UC	marketed		Tyrosine-protein kinase JAK1	2020-01-01
JAK Inhibitor	JAK Inhibitor	Fred Hutchinson Cancer Center	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2
Abrocitinib Suspension F6	abrocitinib-suspension-f6	Pfizer	marketed	JAK inhibitor	JAK1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Janus Kinase Inhibitor [EPC] class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Eli Lilly · 1 drug in this class
Japan Tobacco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABROCITINIB — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl3655081. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab